EA201691602A1 - Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств - Google Patents
Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройствInfo
- Publication number
- EA201691602A1 EA201691602A1 EA201691602A EA201691602A EA201691602A1 EA 201691602 A1 EA201691602 A1 EA 201691602A1 EA 201691602 A EA201691602 A EA 201691602A EA 201691602 A EA201691602 A EA 201691602A EA 201691602 A1 EA201691602 A1 EA 201691602A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- acamprosate
- triggycerides
- baclophene
- neck
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004047 acamprosate Drugs 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 230000006974 Aβ toxicity Effects 0.000 abstract 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000008457 Neurologic Manifestations Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 208000029650 alcohol withdrawal Diseases 0.000 abstract 1
- 229960000794 baclofen Drugs 0.000 abstract 1
- 244000309466 calf Species 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000016273 neuron death Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Настоящее изобретение касается комбинаций и способов лечения неврологических заболеваний, связанных с токсичностью бета-амилоида, и/или гибелью нейронов, и/или нарушением метаболизма глюкозы в нейронах. Более конкретно, настоящее изобретение касается новой комбинированной терапии болезни Альцгеймера, родственных болезни Альцгеймера заболеваний, лобно-височной деменции, болезни Паркинсона, деменции с тельцами Леви, болезни Хантингтона, периферических невропатий, алкоголизма или алкогольной абстиненции, неврологических проявлений злоупотребления наркотиками или абстинентного синдрома, бокового амиотрофического склероза, рассеянного склероза, повреждения спинного мозга, эпилепсии, черепно-мозговой травмы или ишемии головного мозга на основе баклофена, акампросата и по меньшей мере одного среднецепочечного триглицерида.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461938340P | 2014-02-11 | 2014-02-11 | |
PCT/EP2015/052694 WO2015121218A1 (en) | 2014-02-11 | 2015-02-10 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201691602A1 true EA201691602A1 (ru) | 2017-03-31 |
Family
ID=52544464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691602A EA201691602A1 (ru) | 2014-02-11 | 2015-02-10 | Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств |
Country Status (12)
Country | Link |
---|---|
US (1) | US10905672B2 (ru) |
EP (1) | EP3104850A1 (ru) |
JP (1) | JP6619744B2 (ru) |
KR (1) | KR20160111013A (ru) |
CN (1) | CN106456583B (ru) |
AU (1) | AU2015217796B2 (ru) |
CA (1) | CA2938361A1 (ru) |
EA (1) | EA201691602A1 (ru) |
IL (1) | IL246856A0 (ru) |
MX (1) | MX2016010409A (ru) |
SG (1) | SG11201606275WA (ru) |
WO (1) | WO2015121218A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3104850A1 (en) | 2014-02-11 | 2016-12-21 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
KR20170142180A (ko) | 2015-05-04 | 2017-12-27 | 컨플루언스 파마슈티컬스, 엘엘씨 | 아캄프로세이트의 스프링클 제형 |
US20180008612A1 (en) * | 2016-07-11 | 2018-01-11 | Taho Pharmaceuticals Ltd. | Transdermal delivery system containing galantamine or salts thereof |
AU2018236349B2 (en) | 2017-03-15 | 2021-03-11 | Cerecin Inc. | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto |
JP2020519669A (ja) * | 2017-05-17 | 2020-07-02 | コンフルーエンス ファーマシューティカルズ,エルエルシー | ホモタウリンおよびその塩の製剤 |
US20210236445A1 (en) * | 2018-01-29 | 2021-08-05 | Pharnext | Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy |
WO2019178482A1 (en) * | 2018-03-15 | 2019-09-19 | Cerecin Inc. | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto |
CN111166868A (zh) * | 2019-07-17 | 2020-05-19 | 江苏西宏生物医药有限公司 | 一种用于治疗神经疾病和障碍的组合物 |
KR20210072569A (ko) * | 2019-12-09 | 2021-06-17 | 주식회사 종근당 | 도네페질 및 메만틴을 포함하는 복합 제제 |
BR112022021638A2 (pt) * | 2020-05-19 | 2022-12-06 | Nestle Sa | Formulações à base de tcm para melhora das funções cognitivas |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2319508A1 (en) * | 2000-05-01 | 2011-05-11 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
WO2003077902A1 (en) | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
WO2005019163A2 (en) | 2003-08-20 | 2005-03-03 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
US7227028B2 (en) | 2003-12-30 | 2007-06-05 | Xenoport, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
ES2365574T3 (es) | 2007-01-11 | 2011-10-07 | Xenoport, Inc. | Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento. |
WO2009005519A1 (en) | 2007-06-29 | 2009-01-08 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
WO2009033079A1 (en) | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
CA2703831C (en) | 2007-09-07 | 2013-04-16 | Xenoport, Inc. | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
CN101889092A (zh) * | 2007-10-04 | 2010-11-17 | 生物结构实验室公司 | 生物燃料生产 |
WO2009052191A1 (en) | 2007-10-15 | 2009-04-23 | Xenoport, Inc. | Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
US20090118365A1 (en) | 2007-11-06 | 2009-05-07 | Xenoport, Inc | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain |
EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
WO2009096985A1 (en) | 2008-02-01 | 2009-08-06 | Xenoport, Inc. | Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment |
US20100137442A2 (en) | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
CN102065897B (zh) | 2008-04-29 | 2013-11-13 | 法奈科斯公司 | 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用 |
AU2009242126B2 (en) | 2008-04-29 | 2014-03-27 | Pharnext | New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis |
WO2009133128A1 (en) | 2008-04-29 | 2009-11-05 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
EP2403486A1 (en) | 2009-03-03 | 2012-01-11 | XenoPort, Inc. | Sustained release oral dosage forms of an r-baclofen prodrug |
JP2012524065A (ja) | 2009-04-17 | 2012-10-11 | ゼノポート,インコーポレーテッド | GABAB受容体リガンドとしてのγ−アミノ酪酸誘導体 |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
EP2322163A1 (en) | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
ES2532006T3 (es) | 2009-11-20 | 2015-03-23 | Pharnext | Nuevas herramientas de diagnóstico para la enfermedad de Charcot-Marie-Tooth |
WO2011082111A1 (en) * | 2009-12-30 | 2011-07-07 | Baylor Research Institute | Anaplerotic therapy for alzheimer's disease and the aging brain |
EP2705842A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
US9867837B2 (en) | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
RS58114B1 (sr) | 2011-03-01 | 2019-02-28 | Pharnext | Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata |
UA113165C2 (xx) | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
US9931326B2 (en) | 2011-03-29 | 2018-04-03 | Pharnext | Composition comprising torasemide and baclofen for treating neurological disorders |
JP6271539B2 (ja) | 2012-07-18 | 2018-01-31 | ファーネクストPharnext | バクロフェン及びアカンプロセートに基づいた黄斑変性疾患の治療法 |
EP2705841A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
EP2705843A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis |
EP2727587A1 (en) | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
EP3003268B1 (en) | 2013-06-05 | 2018-07-25 | Pharnext | Stable oral solutions for combined api |
WO2015063140A1 (en) | 2013-10-30 | 2015-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
EP3104850A1 (en) | 2014-02-11 | 2016-12-21 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
US9700037B1 (en) | 2014-09-08 | 2017-07-11 | Justin P. Chatelain | Duck decoy device |
US9700036B1 (en) | 2015-04-08 | 2017-07-11 | Justin P. Chatelain | Duck decoy device |
-
2015
- 2015-02-10 EP EP15705551.8A patent/EP3104850A1/en not_active Withdrawn
- 2015-02-10 AU AU2015217796A patent/AU2015217796B2/en not_active Ceased
- 2015-02-10 MX MX2016010409A patent/MX2016010409A/es unknown
- 2015-02-10 US US15/117,774 patent/US10905672B2/en active Active
- 2015-02-10 KR KR1020167025118A patent/KR20160111013A/ko not_active Application Discontinuation
- 2015-02-10 JP JP2016551144A patent/JP6619744B2/ja not_active Expired - Fee Related
- 2015-02-10 SG SG11201606275WA patent/SG11201606275WA/en unknown
- 2015-02-10 CN CN201580008144.4A patent/CN106456583B/zh not_active Expired - Fee Related
- 2015-02-10 CA CA2938361A patent/CA2938361A1/en not_active Abandoned
- 2015-02-10 WO PCT/EP2015/052694 patent/WO2015121218A1/en active Application Filing
- 2015-02-10 EA EA201691602A patent/EA201691602A1/ru unknown
-
2016
- 2016-07-20 IL IL246856A patent/IL246856A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2938361A1 (en) | 2015-08-20 |
WO2015121218A1 (en) | 2015-08-20 |
AU2015217796B2 (en) | 2020-04-30 |
CN106456583B (zh) | 2020-04-07 |
US20160354335A1 (en) | 2016-12-08 |
JP2017505786A (ja) | 2017-02-23 |
MX2016010409A (es) | 2016-11-30 |
AU2015217796A1 (en) | 2016-08-18 |
JP6619744B2 (ja) | 2019-12-11 |
US10905672B2 (en) | 2021-02-02 |
EP3104850A1 (en) | 2016-12-21 |
KR20160111013A (ko) | 2016-09-23 |
IL246856A0 (en) | 2016-08-31 |
CN106456583A (zh) | 2017-02-22 |
SG11201606275WA (en) | 2016-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691602A1 (ru) | Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств | |
CY1120369T1 (el) | Θεραπεια νευρολογικων διαταραχων βασει βακλοφαινης και ακαμπροσατης | |
CO2018009604A2 (es) | Compuesto heterocíclico | |
ECSP19048477A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
ZA202001057B (en) | Inhibiting ubiquitin specific peptidase 30 | |
ECSP19021843A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
MX367023B (es) | Composicion que comprende torasemida y baclofeno para tratar trastornos neurologicos. | |
EA201300975A1 (ru) | Новые композиции для лечения неврологических заболеваний | |
MX2020007318A (es) | Compuesto heterociclico. | |
EP3377118A4 (en) | METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
CL2019001512A1 (es) | Tratamiento de enfermedades neurológicas. | |
WO2019075456A3 (en) | Methods and substances for prevention and treatment of neurodegenerative diseases | |
WO2016042561A3 (en) | Downregulating mir-132 for the treatment of lipid related disorders | |
PH12019502096A1 (en) | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto | |
MY185412A (en) | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system | |
HK1246687A1 (zh) | 治療與帕金遜症治療相關的運動失調及其副作用的方法 | |
MX2020003844A (es) | Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica. | |
BR112016016098A2 (pt) | Compostos orgânicos | |
PH12020551470A1 (en) | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto | |
MX2016016118A (es) | Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo. | |
WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
WO2014111525A3 (en) | Combination therapies for treating nervous system diseases | |
BR112022000874A2 (pt) | Composições e métodos para o tratamento de síndrome de sanfilippo e outras doenças | |
MX2017012239A (es) | Metodos y composiciones para la administracion intravenosa de fumaratos para el tratamiento de enfermedades neurologicas. |